We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Abcam

Abcam is an innovator in reagents and tools, and provides tools and scientific support to the research and clinical c... read more Featured Products: More products

Download Mobile App




Danaher Acquires UK Biotech Company Abcam

By LabMedica International staff writers
Posted on 30 Aug 2023
Print article
Image: Abcam is expected to brand within Danaher’s Life Sciences segment (Photo courtesy of Abcam)
Image: Abcam is expected to brand within Danaher’s Life Sciences segment (Photo courtesy of Abcam)

Danaher Corporation (Waltham, MA, USA) has entered into a definitive agreement to acquire all of the outstanding shares of Abcam plc (Cambridge, UK) for USD 24 per share in cash. The transaction was unanimously approved and recommended by the Abcam board of directors and unanimously approved by the Danaher board of directors.

Founded in 1998, Abcam offers the scientific community a wide range of extensively validated antibodies, reagents, biomarkers, and assays. These resources serve to target key biological pathways critical for the advancement of drug discovery, life sciences research, and diagnostics. The company's technologies find application among approximately 750,000 researchers. Under the planned arrangement, Abcam is poised to continue operating as an independent entity and brand within Danaher's Life Sciences sector. The acquisition of Abcam reflects Danaher's strategy to contribute towards mapping complex diseases and accelerating the process of drug discovery.

“Our strategy has transformed Abcam to become a scale innovator and important catalyst in the global life science community,” said Alan Hirzel, Chief Executive Officer of Abcam. “Danaher shares our passion to help life science researchers achieve their mission faster and their operating company model allows us to continue to pursue our strategy, while harnessing the power of the Danaher Business System to ensure we remain the partner of choice for our customers.”

“We couldn’t be more excited to have Abcam join Danaher,” added Rainer M. Blair, President and Chief Executive Officer, Danaher. “Abcam’s long track record of innovation, outstanding product quality and breadth of antibody portfolio positions them as a key partner for the scientific community. We look forward to welcoming Abcam’s innovative and talented team to Danaher as we continue to help our customers solve some of the world’s biggest healthcare challenges."

Related Links:
Danaher Corporation 
Abcam plc

Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Troponin I Test
Quidel Triage Troponin I Test
New
Dermatophytosis Rapid Diagnostic Kit
StrongStep Dermatophytosis Diagnostic Kit

Print article

Channels

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.